Recent Company News

• 03:05 AM ET Dec 22, 2025
  

  Bayer announces finerenone approved in Japan for treatment of patients with chronic heart failure (pre-EU open) (€35.88, 0.00)

• 04:03 PM ET Dec 19, 2025
  

  Follow-up: Cytokinetics announces FDA approval of MYQORZO in oHCM; call today at 16:30ET ($62.72, 0.00)

• 04:00 PM ET Dec 19, 2025
  

  Cytokinetics announces FDA approval of MYQORZO (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic Cardiomyopathy ($62.72, 0.00)

• 02:41 PM ET Dec 19, 2025
  

  Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation (SEK 29.38, 0.00)

• 03:36 AM ET Dec 19, 2025
  

  Alvotech, Teva reach settlement, license agreement with Regeneron for AVT06 in US; terms undisclosed ($4.73, 0.00)

• 05:54 PM ET Dec 17, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:55 AM ET Dec 17, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:20 AM ET Dec 13, 2025
  

  Biocon signs settlement, license agreement to market Yesafili worldwide; terms undisclosed (INR 386.65, 0.00)

• 12:59 PM ET Dec 12, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 14-Dec

• 08:59 AM ET Dec 12, 2025
  

  EU's CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Bayer's Eylea (€36.46, +0.13)